UNSPSC 51402601: Ipsapirone

This classification denotes a serotonin agonist and anxiolytic with the molecular formula C19H23N5O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6J9B11MN0K, chemically known as 1,2-benzisothiazol-3(2h)-one, 2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-, 1,1-dioxide but generally known as ipsapirone, which bears US NIH Compound Identifier 56971. European Medicines Agency schedules Ipsapirone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08290MIG.

UNSPSC 51402601 Ipsapirone, a Commodity code, maps to pharmaceutical procurement activity that state and local health agencies are buying — though the recent solicitation evidence shows a significant mismatch between the code's nominal scope and what is actually being transacted. Seminole County, Florida posted an IFB in June 2026 for naloxone and safe drug deactivation systems, but neither naloxone nor drug deactivation equipment fall within the ipsapirone pharmaceutical category. State and local health departments, county public health offices, and community health authorities appear to be the primary issuing bodies under this code's nominal scope, though recent activity is sparse and the single tracked opportunity represents a misclassification or data-integrity issue rather than genuine ipsapirone procurement.

The geographic activity is limited to Florida based on the available record. Seminole County's IFB (solicitation number IFB60459723LAS, response deadline July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; bidders were required to submit unit costs, comply with drug-free workplace and E-Verify requirements, and maintain workers' compensation and commercial general liability insurance. The contract carried a two-year initial term with one-year renewal option and a three-month probationary termination clause. The mismatch between the code's pharmaceutical definition and the naloxone/deactivation-systems procurement suggests this code shows little relevant recent state and local activity or reflects a tagging error in the underlying opportunity data.